A backend platform was developed to address the lack of advanced biomanufacturing capacity in the US, allowing biotech companies to raise funds more efficiently and focus on innovation. This platform enabled companies to reduce the amount of capital needed for the first round of funding and allowed for the manufacturing of MRNA and cell therapies. The emergence of companies like Gingikigos highlights the growing need for platforms to support biotech companies in manufacturing without requiring each company to develop their manufacturing capabilities.